PCYC Share Price

Open 260.76 Change Price %
High 261.68 1 Day 1.70 0.65
Low 260.76 1 Week 0.00 0.00
Close 261.25 1 Month 0.00 0.00
Volume 1953837 1 Year 0.00 0.00
52 Week High 6.00
52 Week Low 4.36
PCYC Important Levels
Resistance 2 262.10
Resistance 1 261.75
Pivot 261.23
Support 1 260.75
Support 2 260.40
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Pharmacyclics, Inc. (NASDAQ: PCYC)

PCYC Technical Analysis 5
As on 22nd May 2015 PCYC Share Price closed @ 261.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 158.90 & Strong Buy for SHORT-TERM with Stoploss of 256.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
PCYC Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
PCYC Other Details
Segment EQ
Market Capital 3414584320.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.pharmacyclics.com
PCYC Address
PCYC
999 East Arques Avenue
Sunnyvale, CA 94085
United States
Phone: 408-774-0330
Fax: 408-774-0340
PCYC Latest News
Interactive Technical Analysis Chart Pharmacyclics, Inc. ( PCYC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Pharmacyclics, Inc.
PCYC Business Profile
Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�s tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.